Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

Cancer
Hagop KantarjianHussain Saba

Abstract

Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy. Decitabine indirectly depletes methylcytosine and causes hypomethylation of target gene promoters. A total of 170 patients with MDS were randomized to receive either decitabine at a dose of 15 mg/m2 given intravenously over 3 hours every 8 hours for 3 days (at a dose of 135 mg/m2 per course) and repeated every 6 weeks, or best supportive care. Response was assessed using the International Working Group criteria and required that response criteria be met for at least 8 weeks. Patients who were treated with decitabine achieved a significantly higher overall response rate (17%), including 9% complete responses, compared with supportive care (0%) (P < .001). An additional 12 patients who were treated with decitabine (13%) achieved hematologic improvement. Responses were durable (median, 10.3 mos) and were associated with transfusion independence. Patients treated with decitabine had a trend toward a longer median time to acute myelogenous leukemia (AML) progression or death compared with patients who received supportive care alone (all patients, 12.1 mos vs. 7.8...Continue Reading

References

Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Mar 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P WijermansA Ferrant
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanJames F Holland
Nov 25, 2003·The New England Journal of Medicine·James G Herman, Stephen B Baylin
May 18, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Edvardas KaminskasUNKNOWN FDA
Jul 15, 2005·Seminars in Hematology·Hussain I Saba, Pierre W Wijermans

❮ Previous
Next ❯

Citations

Apr 9, 2008·Annals of Hematology·Andrea Kuendgen, Michael Lübbert
Aug 13, 2008·Annals of Hematology·Catharina Müller-ThomasKatharina S Götze
Feb 20, 2013·Annals of Hematology·Je-Hwan LeeYoung-Don Joo
Feb 21, 2009·International Journal of Colorectal Disease·Yan-Jie ZhangJing-Yuan Fang
Jun 27, 2006·Journal of Gastroenterology·Toshikazu UshijimaTakao Maekita
Feb 24, 2012·Investigational New Drugs·Zarina J D'CostaMerilyn H Hibma
Oct 14, 2010·Journal of Computer-aided Molecular Design·Rafik Karaman
Jun 11, 2011·Journal of Computer-aided Molecular Design·Jakyung Yoo, José L Medina-Franco
Feb 26, 2013·Current Treatment Options in Oncology·Karen Seiter
Jun 12, 2013·Current Treatment Options in Oncology·Gregory M Cote, Edwin Choy
Feb 1, 2007·Current Hematologic Malignancy Reports·Peter D Emanuel
Jan 1, 2008·Current Hematologic Malignancy Reports·L Andres Sirulnik, Richard M Stone
Jan 1, 2009·Current Hematologic Malignancy Reports·Ellen K Ritchie, Mark S Lachs
Jan 1, 2009·Current Hematologic Malignancy Reports·Ahrin Koppel, Gary Schiller
Apr 29, 2010·Current Hematologic Malignancy Reports·Usama Gergis, Usama Wissa
Dec 8, 2010·Current Hematologic Malignancy Reports·Fabio P S SantosFarhad Ravandi
Dec 15, 2010·Current Hematologic Malignancy Reports·Shyamala C Navada, Lewis R Silverman
Mar 29, 2011·Current Hematologic Malignancy Reports·Rami S KomrokjiAlan F List
Aug 19, 2008·Current Oncology Reports·Ahrin Koppel, Gary Schiller
Jan 6, 2012·International Journal of Hematology·Moshe C Ornstein, Mikkael A Sekeres
Oct 12, 2012·International Journal of Hematology·Jumpei Yamazaki, Jean-Pierre J Issa
Apr 1, 2011·Advances in Therapy·Jesus Feliu Sanchez
Dec 7, 2013·Best Practice & Research. Clinical Haematology·Mikkael A Sekeres
Feb 16, 2010·Expert Reviews in Molecular Medicine·Constanze Bonifer, David T Bowen
Mar 3, 2009·Bone Marrow Transplantation·T Kindwall-Keller, L M Isola
Feb 16, 2011·Cell Research·Hsing-Chen Tsai, Stephen B Baylin
Jun 17, 2011·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Xue-Feng XuLi-Zhong Du
Mar 19, 2011·Leukemia·M J WalterT A Graubert

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Lewis R SilvermanJames F Holland
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Lewis R SilvermanCancer and Leukemia Group B
© 2021 Meta ULC. All rights reserved